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ABSTRACT
Although intraperitoneal chemotherapy (IPC) has evolved into an established treatment modality for
patients with peritoneal metastasis (PM), drug penetration into tumor nodules remains limited. Drug
transport during IPC is a complex process that depends on a large number of different parameters
(e.g. drug, dose, tumor size, tumor pressure, tumor vascularization). Mathematical modeling allows for
a better understanding of the processes that underlie drug transport and the relative importance of
the parameters influencing it. In this work, we expanded our previously developed 3D Computational
Fluid Dynamics (CFD) model of the drug mass transport in idealized tumor nodules during IP chemo-
therapy to include realistic tumor geometries and spatially varying vascular properties. DCE-MRI imag-
ing made it possible to distinguish between tumorous tissues, healthy surrounding tissues and
necrotic zones based on differences in the vascular properties. We found that the resulting interstitial
pressure profiles within tumors were highly dependent on the irregular geometries and different
zones. The tumor-specific cisplatin penetration depths ranged from 0.32mm to 0.50mm. In this work,
we found that the positive relationship between tumor size and IFP does not longer hold in the pres-
ence of zones with different vascular properties, while we did observe a positive relationship between
the percentage of viable tumor tissue and the maximal IFP. Our findings highlight the importance of
incorporating both the irregular tumor geometries and different vascular zones in CFD models of IPC.
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Introduction
Cancers originating from organs in the peritoneal cavity are
prone to loco-regional spread in the form of peritoneal
metastasis (PM). The prognosis of patients who develop PM
is usually poor and quality of life is low due to complications,
such as bowel obstructions and ascites. Furthermore, PM
cannot be adequately treated by using intravenous (IV)
chemotherapy due to the poor blood supply to the periton-
eal surfaces and poorly vascularized tumor nodules
(Goodman et al., 2016). Dedrick et al. (1978) hypothesized
that the peritoneum-plasma barrier offers a unique treatment
opportunity for patients with oncological malignancies con-
fined to the peritoneal cavity, introducing intraperitoneal
drug delivery as a therapeutic strategy. Despite a strong
rationale and promising clinical results (Miyagi et al., 2005),
widespread use of the technique is currently hampered by
the limited penetration depth of the drugs into the tumor
tissue (Los et al., 1990; Royer et al., 2012; Ansaloni et al.,
2015). It is, therefore, crucial to gain a better understanding
of the processes that underlie the drug transport and the
relative importance of the parameters influencing it.
Intraperitoneal drug delivery encompasses a complex
transport process that depends on a large number of differ-
ent parameters. The final drug distribution in the tumor tis-
sue is influenced by therapy-related factors such as dose,
temperature, (volume of) carrier fluid, intra-abdominal pres-
sure, the potential use of vaso-active agents or surfactant
and duration. It is also heavily dependent on factors related
to the drug itself like molecular weight, ionic charge, mem-
brane binding, solubility, diffusivity and the on properties of
the tumor tissue (e.g. permeability, vascularity, interstitial
fluid pressure (IFP), cell density, extracellular matrix (ECM)
composition, … ) (Steuperaert et al., 2017). Due to its rela-
tively low cost and versatility, mathematical modeling has
become an important research tool to better understand and
optimize drug delivery. Most existing models of chemothera-
peutic drug delivery, however, have been created for sys-
temic drug delivery (Kim et al., 2013), while only a limited
number of models focuses on intraperitoneal chemotherapy
(Steuperaert et al., 2017). Historically, intraperitoneal drug
transport has often been described using a compartmental
model (El-Kareh & Secomb, 2003; Miyagi et al., 2005; Shah
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et al., 2009; Colin et al., 2014; Goodman et al., 2016), in
which drug concentrations are typically averaged over the
entire tumor. More recent works also take into account spa-
tial variations in drug concentrations on a tissue level
(Flessner et al., 1985; El-Kareh & Secomb, 2004; Flessner,
2005; Stachowska-Pietka et al., 2012; Au et al., 2014;
Steuperaert et al., 2017) and even on the single-cell level
(Winner et al., 2016).
The use of DCE-MRI to gain information about physio-
logical tissue characteristics has been previously applied to
the field of oncology. Pishko et al. (2011) created spatially-
varying porosity and vascular permeability maps from the
two-compartment analysis of DCE-MRI data using a rescaled
AIF from literature. They incorporated these maps in a 3D
computational fluid dynamics (CFD) porous media model to
predict interstitial fluid pressure and velocities (IFP and IFV
respectively) as well as tracer transport in mice sarcomas.
Using the same mathematical model, DCE-MRI dataset and
post-processing techniques, Magdoom et al. (2012) used a
voxelized modeling methodology to eliminate the time-
intensive tumor segmentation step. Zhao et al. (2007) similarly
used DCE-MRI to generate normalized spatial variation maps of
vascular permeability to calculate IFV, IFP, and tracer transport
within a solid murine tumor. The tracer concentration in the
plasma was assumed to be proportional to the relative change
in signal intensity and AIF functions were taken from literature.
The effect of heterogeneous microvessel density extracted
from DCE-MRI on drug concentrations in the extra- and intra-
cellular space studied by Zhan et al. (2014). Using a 2D liver
tumor geometry, the tracer concentration in the plasma was
assumed to be proportional to the relative change in signal
intensity. Bhandari et al. (2017) used DCE-MRI data and patient-
specific AIFs to determine kinetic perfusion parameters in
human brain tumors and predict IFP, IFV, and tracer transport.
Previously, we developed a 3D computational fluid
dynamics (CFD) model that accounts for the diffusive, con-
vective, and reactive drug transport during intraperitoneal
chemotherapy (Steuperaert et al., 2017). We demonstrated
the important influence of both tumor nodule geometry and
interstitial fluid pressure (IFP) on the penetration depth of
cytotoxic drugs in idealized geometries. In this paper, we
extend our previous work and present a workflow to imple-
ment both realistic geometries and IFP profiles in our exist-
ing 3D CFD model. The input for the computational model
was obtained from experiments in a murine cancer model.
The IFP data was obtained both by direct measurements
using a pressure tip catheter and estimated from dynamic
contrast-enhanced magnetic resonance images (DCE-MRI).
The modeled geometries were all mouse-specific based on
anatomical MRI images.
Material and methods
A mouse PM model was used from which tumor geometries
could be obtained and IFP could be measured invasively. As
described in more detail below, we performed an imaging
protocol to monitor tumor growth and to estimate tumor IFP
values from DCE-MRI parameters. Pressure and concentration
distributions were then calculated using the estimated, spa-
tially varying transport parameters obtained based on the
DCE-MRI images. Figure 1 shows a schematic illustration of
the workflow.
All animal experiments were approved by the local Ethics
Committee on Animal Experiments of the Faculty of Medicine,
Ghent University, and were performed according to Belgian
and European legislation on animal welfare (Directive 2010/63/
EU). Animals were group housed and kept under environmen-
tally controlled conditions (12 h light/dark cycles, 20–23 C,
40–60% relative humidity) with food and water ad libitum.
Cell line
Human ovarian cancer cells (SKOV3-Luc-IP1) (De Vlieghere
et al., 2016) were cultured in Dulbecco’s Modified Eagle’s
Medium (Life technologies/ThermoFisher, Ghent, Belgium)
and supplemented with 2% penicillin/streptomycin þ 0.005%
fungizone (Bristol-Myers-Squib B.V., Utrecht, The Netherlands)
and 10% fetal calf serum (Sigma-Aldrich, Diegem, Belgium).
Mouse model
Eight weeks old, female athymic, nude-foxn1nu mice (21 g
average body weight, ENVIGO, NM horst, the Netherlands)
were monitored for general health during one week before
the start of the study. After conditioning, 12 mice underwent
a midline laparotomy under general anesthesia with
Sevoflurane (Baxter, Deerfield, USA) after which they were
bilaterally injected via the subperitoneal route with 5.0 105
SKOV3- Luc-IP1 cells suspended in 50 ll of MatrigelVR (Life
Sciences, Antwerp, Belgium) to facilitate the growth of peri-
toneal tumor nodules (Figure 1(a)). All mice were given sub-
cutaneous pain relief (Ketoprofen, 150ml) immediately after
the procedure. Their weight and general wellbeing were
monitored during recovery.
To assess the success rate of tumor induction and monitor
tumor growth, a bioluminescence scan (IVIS Lumina II, Perkin
Elmer) was acquired 14 days post-injection (Figure 1(b)). Each
animal was injected intraperitoneally with Luciferine (D-
Luciferin, PerkinElmer, Waltham, USA) using a dose of
150mg/kg body weight. During the first scan, a calibration
series was performed to assess the time after injection at
which the signal was maximal. For subsequent scans, the
same waiting period was maintained.
MRI protocol
MRI scanning (Figure 1(c)) was performed using a 7 T MR sys-
tem (PharmaScan 70/16, Bruker, Ettlingen, Germany) with a
mouse body volume coil. During the scanning protocol, all
mice were anesthetized with isoflurane (5% induction, 1.5%
maintenance, 0.3 L/min) and their body temperature was
maintained using a heating blanket. An anatomical scan was
obtained using a T1-weighted sequence (RARE) with the fol-
lowing settings: repetition time (TR) 1455ms, echo time (TE)
9.0184ms, flip angle (FA) 180, in-plane resolution 120 lm,
slice thickness 600 lm, and an acquisition of 30 contiguous
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transverse slices. Using this anatomical scan, a single slice
was chosen in which both tumor nodules were visible.
Native relaxation times were calculated in this slice from a
FLASH sequence with four different TR values, i.e. 100ms,
502ms, 1184ms, and 5000ms. Other scanning parameters
were: TE 100ms, FA 180, in-plane resolution 268 lm. The
DCE-MRI series was acquired for the chosen slice using a
FLASH sequence with TR 12ms, TE 3.4ms, FA 25, in-plane
resolution 268lm, 550 repetitions, and temporal resolution
1.344 s, resulting in a total acquisition time of 12min 19 s.
After 60 s of baseline signal measurements, a bolus of
0.2mmol/kg Gd-DOTA (DotaremTM, Guerbet, Paris, France)
was injected through a tail vein catheter. Animals that did
not show tumor growth were excluded from the rest of
this study.
Intraperitoneal chemotherapy
Three weeks after tumor inoculation, all mice positive for
tumor growth were put under general anesthesia and
underwent 30min of intraperitoneal chemotherapy (IPC)
(Figure 1(d)) with cisplatin (Hospira Benelux BVBA, Antwerp,
Belgium). The administered cisplatin dose was calculated as
1/100th of the clinically used dose relative to the body sur-
face area (BSA) resulting in used values of 0.7mg cisplatin/
mouse (concentration in solution of 113 mmol/l). The cisplatin
solution circulated in a circuit consisting of an inlet and out-
let probe fitted with temperature sensors (TM 9604; Ellab A/
S, Hilleroed, Denmark), a connecting tubing that passed
through a 520U process pump (Watson-Marlow NV,
Zwijnaarde, Belgium) and a M3 LAUDA heat exchanger
(LAUDA-Brinkmann, New Jersey, USA) (Gremonprez et al.,
2015). All procedures were performed on a heating pad and
the chemotherapeutic solution temperature was kept at
37–38 C (normothermic conditions).
Interstitial fluid pressure measurement
Immediately after IPC, the chemotherapeutic solution was
drained from the abdominal cavity, after which the
Figure 1. Schematic illustration of the workflow described in this work. (a) Subperitoneal injection of SKOV3-Luc-IP1 cells suspended in Matrigel in female athymic,
nude-foxn1nu mice by a growth phase. (b) In vivo in situ (IVIS) scan was done 14 days post-injection to assess tumor growth. (c) Scanning protocol as described in
the section MRI protocol consisting of an anatomical scan to segment the tumor geometries, a FLASH sequence to obtain native relaxation times of the tissues and
a DCE-MRI from which vascular parameters of the tumor tissues were derived. The anatomical MRI slice with a red circumference has the same applicate as the
DCE-MRI plane. (d) Mice positive for tumor growth underwent 30min of intraperitoneal chemotherapy (IPC) with cisplatin. The therapy parameters (dose, duration)
that were used in the experiment were used in the model setup as boundary conditions. (e) Immediately after IPC, the IFP was measured using a pressure tip cath-
eter. The resulting pressures were used to validate the simulated tumor pressures in a later stage. (f) The equations for both the IFP build-up using the vascular
parameters derived from the DCE-MRI data and the drug mass transport were implemented in COMSOL and solved using the same initial and boundary conditions
as the experimental setup. The resulting pressure and drug distributions are reported in the ‘results’ section.
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peritoneal surfaces were pat dried. A SPR-320 pressure tip
catheter connected to a PCU-2000 pressure control unit and
PowerLab 35 Series data acquisition system (Millar, Houston,
USA) was manually inserted in the center of each tumor and
held there until a stable pressure output signal was meas-
ured (Gremonprez et al., 2015).
Data processing, fitting, and interpolation
During DCE-MRI scanning, a series of MRI scans are acquired
in rapid succession following the intravenous injection of the
paramagnetic contrast agent. The underlying principle of the
technique relies on the fact that as the contrast agent dis-
perses through the tissue, it changes the MR signal intensity
of the tissue depending on its local concentration.
Following Zhu et al. (2000), T2 relaxation was neglected
to compute the contrast profiles due to the use of short TR’s
and TE’s (rendering the attenuation of signal due to the
terms related to T2 contribution (eTE/T2) negligible for low
contrast concentrations). We thus applied Equation (1a) for
the contrast concentration c:
c ¼ 1
r1TR
log E10
1þ cos að Þ RIE E101ð Þ1ð Þ
RIE E101ð Þ þ E10 1 cos að Þð Þ
" #
(1a)
with
E10 ¼ exp  TRT10
 
(1b)
The relative intensity enhancement (RIE) was calculated as
RIE ¼ SS0S0 with S0 the baseline signal calculated from 60 s of
measurement prior to contrast injection, S the signal at that
timepoint and r1 is the relaxivity of Dotarem (3,5mM
1s1
(http://www.ajnr.org/content/ajnr/suppl/2014/05/22/ajnr.
A3917.DC1/3917_tables.pdf)) in the interstitial fluid, T10 the
native relaxation time calculated from the four images with
different TR, and a is the flip angle. Equation (1a) is solved
for each pixel of the tumorous region of interest (ROI) and
for each timepoint after contrast injection. By tracking the
concentration values of each pixel in function of time, c(t)
profiles can be calculated.
In addition to calculating the concentration profiles of the
contrast agent from the equations above, we can describe
the transient concentration of the Gd-DOTA (cGD) tracer in
the region of interest by a two-compartment model (Zhao
et al., 2007), with the two compartments being the intersti-
tial space and the blood plasma:
u  dcGD
dt
¼ P S
V
cAIFcGDð Þ þ JvV 1 rð ÞcAIF (2)
in which cGD and cAIF are the concentrations of the tracer in
the interstitial space and the plasma, respectively. cAIF is also
known as the arterial input function (AIF). u is the interstitial
fluid volume fraction, P is the permeability coefficient of the
vasculature for the tracer, SV is the surface to volume ratio of
the vasculature, r the osmotic reflection coefficient for the
tracer, and JvV the plasma filtration rate per unit volume. In
order to obtain a good estimate for the parameters u; P SV
and JvV ; it is crucial to provide an AIF that is as accurate as
possible. To extract a mouse-specific AIF from the DCE-MRI
dataset, a high temporal resolution is needed throughout
the series. This in turn, limits the spatial resolution that can
be achieved in the DCE-MRI plane. To obtain the AIF,
Equation (1) was again used to calculate the contrast con-
centration on candidate AIF pixels that were identified on
the anatomical image. The contrast concentration calculated
in these pixels represents the blood concentration of con-
trast (cb) so to obtain the plasma concentration of contrast
(cAIF), an additional scaling had to be performed, taking into
account the hematocrit value (Hct) of the mouse (Equation
(3)) (Tofts & Parker, 2013).
cAIF ¼ cb1 Hct (3)
The resulting plasma concentration curve was then fil-
tered and fitted to a bi-exponential curve that was further
used in its analytical form as the AIF. Using the correspond-
ing mouse-specific AIF for each tumor ROI, the solution to
this first-order differential equation (cGD, Equation (2)) can be
fitted on a voxel to voxel basis to the contrast profiles that
were calculated from the DCE-MRI (Equation (1a)) series to
obtain estimates for u; P SV and
Jv
V :
To implement spatially varying vascular parameters in our
model we used an approach previously described by Zhao
et al. (2007) in which the JvV values are rescaled to the prod-
uct of the vascular hydraulic conductivity and surface-to-vol-
ume ratio of the microvasculature Lp SV : In order to do so, all
Jv
V values were first normalized with respect to the average
value ðJvVÞmean of all fitted pixels in the ROI and then scaled
by multiplying the normalized values with the product of the
baseline values typically used for hydraulic conductivity and
vascular surface to volume ratio in literature (Gremonprez
et al., 2015) (Lp;o ¼ 2:1 1011 mPas ; SV
 
0 ¼ 2:00 
104 m1Þ (Equation (4)).
LpS
V
 
i;j
¼ Lp;0  SV
 
0

Jv
V
 
i;j
Jv
V
 
avg
(4)
The extrapolated LPSV values were then used as input for
the Starling term in our model for IF flow (see further).
The need for a high temporal resolution (to extract the
AIF from the data) and the available MRI hardware, limited
us to a 2-dimensional DCE-MRI series. To provide 3D spatially
varying parameters, extrapolation of the available data was
needed. Upon inspection of the estimated resulting param-
eter maps, two distinctively different regions could be
detected in each tumor. In tumors 1 and 2, there were inter-
ior zones with pixels that could not be fit by Equation (2),
whereas the surrounding tissue was fit well by the same
equation. In tumor 3 on the other hand, the majority of
interior pixels was well fit but two zones for which the LPSV
parameter yielded very different results, could be distin-
guished. These different regions were then related back to
the anatomical scans (T1 weighed scans) and traced in each
slice of the anatomical scan of the tumor geometry thereby
effectively segmenting a second 3D zone within the original
tumor. The mean LPSV value averaged over all fitted pixels in
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the sub-ROI was then assigned to each of the different
regions. Implications of this extrapolation will be discussed
in the discussion section.
Computational model
For this work, three different tumors were selected based on
their respective. The tumor geometries were segmented
using Mimics (Materialise, Leuven, Belgium) and the resulting
geometries were smoothed and meshed in 3-Matic
(Materialise, Leuven, Belgium) before they were imported as
stl-files in COMSOL Multiphysics (COMSOL, Inc., Burlington,
USA). A similar procedure was followed to obtain the bound-
ary of any additional internal zones that were present in the
tumors. Volume meshes where created in COMSOL
Multiphysics using the same element size for each geometry
(1.7 104mm3) based on the mesh independence study of
the model, resulting in the mesh sizes listed in Table 1. The
equations for both the IFP build-up and the mass transport
that were implemented in COMSOL were previously
described by our group (Steuperaert et al., 2017) and sum-
marized below. In a rigid porous medium like the tumor
interstitium, the momentum equation can be reduced to
Darcy’s Law (Bird et al., 2007):
u ¼ KrPi (5)
where u represents the interstitial fluid velocity vector (in
m/s); K the conductivity of the tissue for interstitial fluid
(3.1 1014 m2/Pa s (Baxter & Jain, 1989)), Pi the interstitial
fluid pressure (Pa) and r the gradient operator.
The steady-state continuity equation for the incompress-
ible interstitial fluid flow in normal tissue is given by (Bird
et al., 2007):
r  u ¼ Fv  Fl (6)
were r represents the divergence operator; Fv the fluid gain
from the blood (s1) and Fl a lymphatic drainage term for
interstitial fluid (s1). Since there is a known lack of func-
tional lymphatics in solid tumors, Fl ¼ 0: The constitutive
relation for Fv is based on Starling’s hypothesis (Baxter &
Jain, 1989) (Equation (7)):
Fv ¼ LpSV PvPic pvpið Þ
 
(7)
with Lp the hydraulic conductivity of the vasculature (m/
Pas), S/V the surface to volume ratio of the vasculature
(m1), Pv the vascular pressure (Pa), Pi the interstitial fluid
pressure (Pa), c the non-dimensional osmotic reflection coef-
ficient, pv the vascular osmotic pressure (Pa) and pi the inter-
stitial osmotic pressure (Pa). IFP profiles were calculated by
solving the steady state form of the momentum and con-
tinuity equations. When more than one zone was present in
the tumor, the source and sink terms (i.e. Starling source)
were adapted in each zone to include the corresponding
estimated LpS/V value as discussed in the ‘data process-
ing’ section.
Mass conservation of the drug is given by Equation (8)
(Bird et al., 2007):
oCdrug
ot
¼ Dr2Cdrug r  uCdrugð Þ  S (8)
with Cdrug the time-dependent concentration of the drug pre-
sent in the interstitium (mol/m3), D the diffusion coefficient
(m2/s), r2 the Laplacian operator, r the divergence oper-
ator and S the sink in drug concentration (mol/m3). This sink
term includes losses due to cellular uptake and resorption by
the vascular system (Steuperaert et al., 2017). To calculate
the IF flow, the pressure at the outer edge of the tumor is
Table 1a. Geometrical properties of the three segmented geometries.
Tumor 1 Tumor 2 Tumor 3
Geometrical properties
Tumor location Right Left Right
Tumor Size 8  11mm 6  8mm 4  6mm
Reconstructed tumor volume 288mm3 121mm3 45mm3
Reconstructed interior volume 69mm3 9mm3 8mm3
Mesh size (number of volume elements) 1693526 715057 421569
#pixels in DCE-MRI ROI 329 270 181
Table 1b. Summary of pressure and penetration depth results.
Tumor 1 Tumor 2 Tumor 3
SA1 SA2 LA SA LA SA LA
Pressure and concentration results
Pmeas(Pa) 2067 2890 2533
Pmax (Pa) 1385 1429 1411 1523 1525 1428 1468
LP50 (mm) L: 0.0437 L: 0.0407 L: 0.0290 L: 0.0565 L: 0.0365 L: 0.0819 L: 0.0727
R: 0.0428 R: 0.0351 R: 0.0401 R: 0.0519 R: 0.0378 R: 0.0708 R: 0.0603
APD (mm) L: 0.361 L: 0.320 L: 0.412 L: 0.370 L: 0.422 L: 0.371 L: 0.495
R: 0.331 R: 0.327 R: 0.404 R: 0.328 R: 0.281 R: 0.394 R: 0.463
PD% (%) L: 5.63% L: 5.50% L: 5.33% L: 7.96% L: 4.96% L: 10.3% L: 7.92%
R: 5.16% R: 5.68% R: 5.23% R: 6.85% R: 3.30% R: 10.9% R: 7.41%
Pvol% (%) 28.04% 31.32% 43.42%
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kept constant at 0 Pa and at the interface between two dif-
ferent tumor zones, an interface boundary condition is
imposed, implying continuity of all properties. On the edge
of the tumor nodule, where the IPC drug is in direct contact
with tumor tissue, a fixed drug concentration is maintained
(i.e. 0.113mol/m3). Initial values for pressure and concentra-
tion in the domain were set to 0 Pa and 0mol/m3, respect-
ively. Values for all model parameters mentioned above were
taken from our previously published model of the drug dis-
tribution in a single tumor nodule during IP chemotherapy
(Steuperaert et al., 2017).
A segregated approach was used for solving the continu-
ity equation, momentum transport, and mass conversation of
the drug. All three tumor cases were run as transient models
with a time resolution of 30 s. As a convergence criterion, a
drop of 4 orders of magnitude in the residuals was chosen.
Reported parameters
By solving the drug transport equation (Equation (8)) using
the pressure and velocity field calculated in the previous sec-
tion, drug concentrations could be determined in the
tumor geometries.
For all simulations, pressure and concentration profiles
were analyzed along 2 or 3 perpendicular axes in the XY-
plane with the same applicate as the one of the DCE-MRI
planes. All lengths reported are distances that are normalized
with respect to the corresponding length of the axis. The
pressure profile along a certain axis is characterized by the
maximal pressure (Pmax) along this axis and the steepness of
the pressure profile in that direction. In this work, the steep-
ness is characterized by the LP50 value, which we define as
the distance starting from the tumor edge after which the
pressure reaches 50% of its maximal value. The steeper the
pressure profile, the lower the LP50 value will be.
From the concentration profiles along the axes, the pene-
tration depth is determined. Both absolute penetration
depths (APD) and relative penetration depth percentages
(PD%) are reported. The APD is defined as the maximal
depth along the axis of interest where the drug concentra-
tion exceeds the corresponding half maximal inhibitory con-
centration value of the drug (IC50). The PD% represents the
percentage of the length of the axis where concentration
values exceed the corresponding IC50 value of the drug
used. The inclusion of different zones with varying vascular
properties results in non-symmetric profiles along the axes.
To highlight this phenomenon, values for the penetration
depths are reported with respect to both sides of the axis
(L¼ smallest abscissa; R¼ largest abscissa).
Results
Geometry and segmentation
The three selected tumors significantly differed in size with
reconstructed tumor volumes ranging from 45mm3 to
288mm3. Tumor 1 was the largest with a volume of
288mm3. The interior zones that can be seen in Figure 2 can
be related to the zones with varying vascular properties that
were segmented and ranged in volume from 8mm3 for
tumor 3–69mm3 for tumor 1. The number of pixels in the
tumor ROI of the DCE-MRI images varied from 181 to 329. A
summary of the geometric properties of the different tumors
is presented in Table 1(a).
Data processing
For each of the 3 chosen animals, a suitable AIF could be fit-
ted from the concentration data. Using the animal-specific
AIF, the parametric solution for Equation (2) was calculated
and subsequently fitted to all pixels within the ROI (ROI
tumor 1: Figure 3(b), ROI tumor 2: Figure 3(h)). Upon fitting
the pixels of the tumor ROI, we found that certain pixels
were not adequately fitted (R2< 0.85) (red pixels in Figure
3(c,i)). The contrast concentration c(t) increased fastest in the
viable tissue areas as a result of rapid Gd-DOTA uptake in
this well-perfused region, followed by rapid washout (Figure
3(e,k)). In hypoxic areas, however, there is typically a reduced
vascularization which is reflected in a delayed Gd-DOTA sig-
nal build-up as well as a delayed and prolonged wash-out of
signal (Figure 3(l)). In necrotic regions of the tumor, there is
no vascularity thought to be present and no washout of the
contrast agent could be seen in the signal (http://www.ajnr.
org/content/ajnr/suppl/2014/05/22/ajnr.A3917.DC1/3917_
tables.pdf) (Figure 3(f)). Unlike pixels in the hypoxic and
viable tissue areas, pixels in necrotic areas were not
adequately fitted by Equation (2). For the pixels that were
adequately fitted, Jv/V parameter maps were created and
scaled to LpS/V maps (Figure 3(d,j)). Upon inspection of the
resulting LpS/V maps different zones within the tumor nod-
ules could be identified (hypoxic/necrotic/viable tissue). The
LpS/V-values were then averaged over the different zones
and the final values ranged from 0 in the necrotic areas to 3.
946 107 (Pa s)1 in the outer zone of tumor 3.
Pressure measurement
The measured pressures in the three tumors were
15.5mmHg (2067 Pa), 21.3mmHg (2890 Pa) and 19mmHg
(2533 Pa) for tumor 1, 2 and 3, respectively. In Table 1(b), the
converted pressure values in Pa are summarized.
Pressure simulation
The model can calculate IFP pressures and concentration dis-
tributions in all geometries. The maximal IFP (Table 1(b))
reached in our simulations was 1525 Pa (11.44mmHg),
obtained in tumor 2. The shape of the pressure profiles
(Figure 4) differed strongly between the different tumor geo-
metries and even along the longer and shorter axes in the
same tumor geometry. It is interesting to note that the pres-
sure profile along the short axis 1 of tumor 1 has a local
minimum. Another pressure related parameter that showed a
directional variability was the LP50 with a peak value of
0.819mm for the left side of the long axis of tumor 3 and a
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minimum of 0.0290 for the left side of the long axis
of tumor 1.
Drug distribution
Drug penetration was analyzed along the same axes men-
tioned above and all concentrations were normalized with
respect to the initial concentration c¼ 113mmol/l. Absolute
penetration depths ranged from 0.281mm to 0.495mm and
were highest along the long axis of tumor 3 and lowest
along the long axis of tumor 2. Relative penetration percent-
age ranged from 3.30% to 10.9% and was highest along the
short axis of tumor 3 and lowest along the long axis of
tumor 2. The volume fraction of penetrated tumor tissue
ranged from 28.04% to 43.42% and was highest for tumor 3
and lowest for tumor 1. A summary of the penetration
depths can be found in Table 1(a,b) visualization of the drug
concentration profiles can be found in Figure 5.
Discussion
In this work, we expanded our previously developed three-
dimensional CFD model for IPC in tumor nodules
(Steuperaert et al., 2017) to include realistic geometries and
pressure profiles. We modeled three different tumor nodule
geometries of different sizes (288mm3, 121mm3, 45mm3)
and extracted spatially varying microvasculature related
parameters from DCE-MRI images. Using these parameters,
pressure fields were simulated in the tumors and drug trans-
port was studied in all three tumor geometries in the pres-
ence of the corresponding pressure field.
In any work relying on DCE-MRI data, a tradeoff has to be
made between spatial and temporal resolution (Barnes et al.,
2012). We opted for a small temporal resolution to extract
an animal-specific AIF. Due to this high temporal resolution
and the available MRI hardware, we were limited to a single
slice and had to extrapolate the vascular properties esti-
mated from this slice to three-dimensional data. Other works
in which mice tumors were studied have used AIF functions
from literature to allow for a lower temporal resolution
(Zhao et al., 2007; Pishko et al., 2011; Magdoom et al., 2012).
The extrapolation of data from 2D to 3D inevitably leads to
inaccuracies in the determination of the interior tumor zones
that were determined. In the future, a more realistic estima-
tion of vascular parameters in the tumors could be obtained
using multiple slices throughout the tumor during the DCE-
MRI and applying the data processing workflow for each
slice. Recently, Bhandari et al. (2018) used a 3D DCE-MRI
Figure 2. Visualization of the three segmented tumor geometries and their different zones on a common scale. The tumors have reconstructed volume values of
288, 121 and 45mm3, respectively.
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sequence combined with a high temporal resolution in the
study of human brain tumors with good results. It is, how-
ever, impossible to compensate for physiological and hard-
ware differences by extrapolating scan parameters from one
setup to another. We found that, upon fitting the DCE-MRI
data to Equation (1), not all pixels could be adequately fit. In
some cases, this was due to poor signal quality (too much
noise) in these pixels and for the second subset of pixels,
located at the edge of the ROI, this was because of overesti-
mations in the initial ROI segmentation, most likely caused
by partial volume effects (Ballester et al., 2002). Studying the
contrast concentration profiles in the border areas of the ini-
tial ROI’s could in the future allow for a better distinction
between tumor and surrounding tissue and a more
refined ROI.
A final group of pixels that could not be fit by Equation
(2) were pixels that exhibited the typical signal shape of nec-
rotic zones. Both tumor 1 and tumor 2 were found to have
necrotic cores, with the pixels in the dark regions on
Figure 3 exhibiting the typical relation between time and sig-
nal intensity for necrotic zones as was also found in (Cho
et al., 2009). The necrotic zone in tumor 1 (largest tumor),
however, was estimated to be a factor 8 larger than the one
in tumor 2.
In tumor 3, two different zones could also be distin-
guished (Figure 2), but neither of them was necrotic. Pixels
from the interior zone of tumor 3 displayed a relation
between time and signal intensity that was more close to
that of a hypoxic zone with a slower contrast uptake and a
prolonged wash-out compared to perfused tumor tissue.
Contrast concentration curves of pixels belonging to the
outer shell of each of the three tumors followed the typical
relation for viable, well-perfused tumor tissue with a sharp
peak in contrast concentration and a rapid wash-out due to
the abundance of leaky, tortuous microvasculature in
this area.
Figure 3. (a) Baseline DCE-MRI image of the tumor 1 ROI. (b) Mask created of tumor 1 ROI based on the baseline image. (c) Visualization of the pixels within the
tumor 1 ROI that were adequately fit (R2> 0.85) in green and the ones that could not be fit in red. (d) LpS/V map of the tumor 1. (e) Representative c(t) profile for
the pixels in the darker, viable tissue zone of image 3d. (f) Example of a c(t) profile for the pixels in the white, necrotic tissue zone of image 3d. Tumor 2 is not
included in the figures, but Representative c(t) profiles are similar to the ones obtained in tumor 1 with both a viable and necrotic tumor tissue zone, albeit of dif-
ferent size and shape. (g) Baseline image of the tumor 3 ROI. (h) Mask created of tumor 3 ROI based on the baseline image. (i) Visualization of the pixels within the
tumor 3 ROI that were adequately fit (R2> 0.85) in green and the ones that could not be fit in red. (j) LpS/V map of the tumor 3 with two distinctive zones that
can be noted. (k) Representative c(t) profile for the pixels in the viable tissue zone of image 3j. (l) Example of a c(t) profile for the pixels in hypoxic tissue zone of
image 3j.
DRUG DELIVERY 411
The measured pressures varied between 2066 Pa and
2839 Pa with the largest value observed in tumor 2 and the
smallest value in tumor 1. Overall, the lower the LP50, the
steeper the pressure profile and the higher the maximal
interstitial fluid velocity, and therefore the higher the radial
outward convective flow will be. Calculated pressures
showed a similar trend but were lower with values varying
from 1384 Pa to 1525 Pa (largest value for tumor 2, smallest
value in tumor 1). Tumor 2, which had the largest percent-
age of viable, well-perfused tumor tissue, presented with the
highest IFP. It is important to note that in the CFD model
only IFP is simulated by means of the Starling term.
However, the invasively measured pressure yields the total
pressure, i.e. the sum of the IFP and solid state (SS) pressure
(Boucher & Jain, 1992) with the SS pressure transmitted by
the solid and elastic elements of the extracellular matrix and
cells, as opposed to fluids (IFP). The difference between the
measured and predicted IFP pressure may be a measure for
the SS matrix pressure that exists in solid tumors
(Stylianopoulos, 2017). Nonetheless, validation of this
assumption is mandatory but not trivial, as most invasive
pressure measurements will correspond to the total stress
rather than one of its components. Deformation tests per-
formed by Nia et al. (2016) estimated the solid stress in solid
tumors of colorectal and pancreatic origins to be in the
range of 90–1000 Pa. Given this order of magnitude of the
SS pressure as an indication, the SS pressure may explain the
difference between the simulated IFP and the measured total
pressure. Assuming that indeed the SS stress can be calcu-
lated as the experimentally measured total stress minus the
calculated IFP, the SS pressures in the three tumor geome-
tries equals 682 Pa for tumor 1, 1367 Pa for tumor 2, and
1105 Pa for tumor 3. Due to the differences in extracellular
matrix (ECM), cell density and the presence of cancer-associ-
ated fibroblasts (CAFs), the tumor tissue permeability is likely
to be significantly different from the healthy surrounding tis-
sue permeability. While we previously found that the IFP
remained virtually constant when the Darcy permeability of
the tissue changed, these changes are very likely to impact
the SS pressure. To obtain a tumor-specific estimate of the
SS pressure to add to the calculated IFP, an extra step could
be added to the workflow in future work where – using a
similar workflow as described by Helmlinger et al. (1997) and
Stylianopoulos et al. (2012) – the tumor deformation after
cutting is used to determine the SS pressure.
The invasively measured total pressures in the tumors were
within the range of previously measured pressures in tumors
of similar size, location and origin (11mmHg–40mmHg with a
median of 22mmHg (Gremonprez et al., 2015) which equals a
range of 1497–5333Pa with a median of 2933Pa).
In our previous work (Steuperaert et al., 2017), we estab-
lished a positive relationship between tumor size and max-
imal IFP. In this work, we found that this relationship does
not longer hold in the presence of zones with different vas-
cular properties, while we did observe a positive relationship
between the percentage of viable tumor tissue and the max-
imal IFP. This is of particular interest as a recent work by
Bhandari et al. (2018) found no relation between tumor size
and IFP. The different IFP values found for different tumor
volumes in this work are thought to be due to the maximal
IFP being reached in the geometries being lower than the
maximal possible IFP. When this maximal pressure value is
reached, the net volume flux out of the vasculature is zero
and exceeding this pressure value would most likely result in
Figure 4. Pressure distributions in the different tumor geometries along the short and long axes (SA and LA, respectively) presented at the bottom; tumor projec-
tions are not to scale. Pressures are noted in Pa and the distances are normalized with respect to the total respective length of the axis.
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the local collapse of the microvasculature. This maximal IFP
value can be found by equaling the filtration rate of plasma
fluid per unit volume (JV/V) across the vessel wall as
described by Starling’s law to zero.
Jv
V
¼ LpS
V
PvPic pvpið Þ
 
This results in the following maximal IFP: Pi,
MAX=Pvc(pvpi) in which Pv is the vascular pressure, c the
osmotic reflection coefficient and pv and pi the oncotic pres-
sures in blood and interstitium, respectively. Using the
parameters used in this work, this maximal interstitial pres-
sure value equals ± 1530 Pa. The pressure obtained in the
tumors described in the work of Bhandari et al., is close to
the maximal interstitial pressure. Therefore, it is not expected
that IFP will be different between different tumors geome-
tries in the work of Bhandari et al. We also noted that the
presence of the 3D necrotic zones resulted in heterogeneous
IFP profiles in the tumors. We also noted that the presence
of the 3D necrotic zones resulted in heterogeneous IFP pro-
files in the tumors. These findings are of specific interest as
previous works using symmetrical, idealized tumor and nec-
rotic core geometries, found little to no influence of the nec-
rotic core on the IFP profile (Baxter & Jain, 1990). A similar
finding was done by Pishko et al. (2011), where skewed IFP
values were reported based on IFP calculations using 3D spa-
tially varying tissue parameters.
The absolute penetration depths calculated in this work
ranged from 0.32mm to 0.50mm. When comparing these
results with those obtained in previous studies, they were
found to be in good agreement with the experimentally
defined range of 0.41–0.56mm where carboplatin (another
platinum-based drug of roughly the same size) was used
(Ansaloni et al., 2015). The observed concentration profiles
were highly dependent on both the probing location and
direction. We calculated the volume percentage of each
tumor where the local drug concentration after 30min of IPC
exceeded the IC50 value of cisplatin (De Vlieghere et al.,
2016) and found a range of 28.04–43.42%, with the highest
percentage occurring in tumor 3 and the lowest in tumor 2.
In our previous work, we explored the relative importance of
several different parameters that influenced the drug trans-
port during IPC. One of the largest improvements in penetra-
tion depth was obtained by subjecting the tumor nodules to
vascular normalization (VN) therapy with the APD doubling
in certain cases. The results in this work indicate that pene-
tration depths in certain tumors (i.e. tumor 3) could reach up
to 47% when doubled and might be very good candidates
for VN therapy.
As in all numerical models, some assumptions were made
to make the model implementable. The model may incorpor-
ate different zones with different vascular parameters, but
the reality is more complex. Using a higher spatial resolution
and multiple slices (instead of 1 slice) to obtain DCE-MRI
data throughout the tumor should allow for a more realistic
distribution of vascular parameters in the tumors, possibly
on a voxel per-voxel basis. The estimates for LpS/V could be
further refined by coupling model equations to the compart-
mental model that would yield a direct estimation of LpS/V
values from the tracer signal instead of the proportionality to
Figure 5. Drug distribution in the different tumor geometries along the axes as shown in the bottom; tumor projections are not to scale. Concentrations are noted
in mol/m3 and the distances are normalized with respect to the total respective length of the axis.
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Jv/V approximation (Zhao et al., 2007). The model could be
further refined by the addition of sink terms that represent
the effect of other physiological phenomena, such as drug
binding to the ECM and plasma protein binding.
Additionally, a number of refinements could be made to the
boundary conditions of the model, such as the inclusion of
time-dependent boundary concentrations to take into
account the changing concentration of drug in the carrier
fluid and non-zero boundary pressures to take into account
the hydrostatic pressure head of the fluid in the abdomen.
An additional sensitivity study using this model may include
changing the drug concentration boundary concentration
over a biologically relevant range to quantify possible pene-
tration depth enhancements by using higher concentrations.
The results presented in this work are based on data
obtained from three tumors in a mouse model. Applying the
same workflow, with the possible inclusion of some of the
adaptations mentioned above, to a larger group of animals
would allow for the determination of a population-based
average of the AIF and could also shed more light on the
extent of tissue heterogeneity within different tumor geome-
tries of the same origin. Applying the same protocol to
human subjects should be feasible but there are a few
aspects to take into consideration. Although DCE-MRI
sequences for human tumor imaging exist, the location of
the PM makes them susceptible to motion artifacts due to
both respiration and peristaltic movement which could inter-
fere with data quality. Additionally, the noninvasive pressure
estimation presented in this work only estimated IFP pres-
sures and does not account for SS pressures. To obtain an
accurate, noninvasive estimation of total tumor pressure, the
SS should be estimated noninvasively as well.
In conclusion, we expanded our previously developed 3D
CFD model of the drug mass transport in a single tumor nodule
during IP chemotherapy to include realistic tumor geometries
and spatially varying vascular properties. DCE-MRI studies
made it possible to distinguish between tumorous tissues with
different vascular properties as well as the healthy surrounding
tissues and necrotic zones. We found that tumor size no longer
correlated to the maximal IFP when regions with different vas-
cular properties were included. Using realistic geometries of
both tumor nodules and necrotic cores had a big impact on
the resulting penetration depth in this work, unlike the previ-
ous model in which the inclusion or absence of a necrotic core
did not seem to influence the penetration depth significantly.
We found that the resulting pressure profiles within tumors
were highly dependent on the irregular geometries and differ-
ent zones, indicating a strong need to include both aspects in
the model. The total pressure was found to be higher for
higher percentages of viable tumor tissue volume ratios. The
presence of a significant solid-state pressure in the tumor nod-
ules may explain the difference between calculated IFP pres-
sures and measured total pressures.
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